GUARDANT360 Tissue

Now available from Guardant Health:
A full suite of IHC testing.*

Refer to the list of guideline-recommended IHC biomarkers by tumor type below,
and select them directly on your order form.

Lung	Breast	Colorectal	Gastric	Ovarian
c-MET, HER2, PD-L1	**ER/PR, HER2, Ki-67, MMR†, PD-L1**	**MMR, HER2**	**CLDN18, HER2 MMR, PD-L1**	**FOLR1, HER2, MMR**

>20% improved PD-L1 detection with AI-powered scoring.‡[1]

IHC, Immunohistochemistry.
* Currently, only PD-L1 is available in NY State.
† Guidelines state MMR is useful in certain circumstances for breast cancer patients who have no satisfactory alternative treatment options.
‡ Compared to manual pathologist interpretation in the most challenging cases of NSCLC.
Reference: 1. Choi S, et al. Eur J Cancer. 2022;170:17-26. doi:10.1016/j.ejca.2022.04.011

Get IHC results as an add-on to Guardant360 Tissue.[§]

IHC sample requirements:

1 unstained slide each

c-MET, FOLR1, HER2, Ki-67, PD-L1

2 unstained slides each

CLDN18, ER/PR[‖]

4 unstained slides



MMR

Convenient ordering

Easily add IHC tests to a Guardant360 Tissue order via the paper order form, online portal, or EMR.[§]

3-5 day turnaround time[¶]

EMR, electronic medical record.

[§] IHC results are issued as a separate clinical report.

[‖] ER/PR are ordered together and require one unstained slide each for a total of 2 unstained slides.

[¶] Median turnaround time from sample receipt to results.

Important note: Guardant360 Tissue and Guardant Galaxy PD-L1 were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.

GUARDANT™